Fisker Announces Timing of Fourth Quarter and Full Year 2022 Results and Webcast

Fisker Inc. (NYSE: FSR) ("Fisker") driven by a mission to create the world's most emotional and sustainable electric vehicles today announced that it will report its fourth quarter and full year 2022 financial results after market close on Monday, February 27, 2023. The release will be followed by a conference call at 2 p.m. PT (5 p.m. ET). Speakers on the call will be Henrik Fisker, Chairman and Chief Executive Officer; Dr. Burkhard Huhnke, Chief Technology Officer; and Dr. Geeta Gupta-Fisker, Chief Operating Officer and Chief Financial Officer of Fisker Inc.

The conference call can be accessed via a live webcast accessible on the Events and Presentations page of Fisker's Investor Relations website: https://investors.fiskerinc.com/ . An archive of the webcast will be available shortly after the call and will remain on the website for 12 months thereafter.

In addition, Fisker will once again provide shareholders the ability to submit and upvote questions to management through a shareholder Q&A platform. To submit questions ahead of earnings, please visit the Say platform here ; shareholders at brokers with Say can participate directly in their investing app or broker website. The Q&A platform will remain open until 24 hours before the earnings call and can also be accessed in the Events & Presentations section of Fisker's IR website. Management intends to respond to a selection of questions during the Q&A portion of the call.

About Fisker Inc.

California-based Fisker Inc. is revolutionizing the automotive industry by developing the most emotionally desirable and eco-friendly electric vehicles on Earth. Passionately driven by a vision of a clean future for all, the company is on a mission to become the No. 1 e-mobility service provider with the world's most sustainable vehicles. To learn more, visit www.FiskerInc.com – and enjoy exclusive content across Fisker's social media channels: Facebook , Instagram , Twitter , YouTube , and LinkedIn .

Download the revolutionary new Fisker mobile app from the App Store or Google Play store.

Fisker Inc. Communications:

Matthew DeBord
Sr. Director, Communications Strategy & Storytelling
mdebord@fiskerinc.com

Rebecca Lindland
Director, Communications
rlindland@fiskerinc.com

Franziska Queling
Regional Head of Public Relations Europe
fqueling@fiskerinc.com

Investor Relations:

Frank Boroch, VP of Investor Relations
fboroch@fiskerinc.com

News Provided by Business Wire via QuoteMedia

FIS
The Conversation (0)
Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

Brunswick Continues to Intersect Lithium Mineralization on Globex's Lac Escale Royalty Property

GLOBEX MINING ENTERPRISES INC. (GMX Toronto Stock Exchange, G1MN Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, DĂĽsseldorf and Quotrix DĂĽsseldorf Stock Exch anges and GLBXF OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (BRW-TSXV, BRWXF-OTCQB) in a press release today, announced additional wide intersections of lithium mineralization on Globex's Lac Escale royalty claims, a part of Brunswick's Mirage property.

Intersections include 36 meters grading 1.51% Li 2 O in Hole MR-24-102 and 1.32% Li 2 O over 28 metres in Hole MR-24-101. A total of 24 drill holes were completed in the winter drill program. Please access Brunswick's press release of today's date for further details.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep.

The company has successfully completed a two sheep protocol pilot trial in November 2023, and is now preparing to expand the study. The ZC-1-A device was confirmed as 100% safe for use, with findings concluded from the Shamir Medical Center.

Keep reading...Show less

Latest Press Releases

Related News

Ă—